Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H20BN3O3.C4H6O6 |
Molecular Weight | 391.182 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.OB(O)[C@@H]1CCCN1C(=O)CN[C@@H]2CCNC2
InChI
InChIKey=SVWHNLVZPGXBNS-MHDNXTQBSA-N
InChI=1S/C10H20BN3O3.C4H6O6/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17;5-1(3(7)8)2(6)4(9)10/h8-9,12-13,16-17H,1-7H2;1-2,5-6H,(H,7,8)(H,9,10)/t8-,9+;1-,2-/m11/s1
Dutogliptin (PHX-1149T) is a small-molecule dipeptidyl peptidase-4 (DPP-4) inhibitor for the potential oral treatment of type 2 diabetes mellitus (T2DM). DPP-4 quickly degrades the insulin secretory hormones, glucose-dependent insulinotropic peptide and glucagon-like peptide-1; thus inhibiting the degradation of these hormones is a viable treatment option for patients with T2DM. In preclinical studies, dutogliptin potently inhibited DPP-4 and, in a model of T2DM, treatment with dutogliptin improved glucose homeostasis. Pharmacokinetic analyses in animals, healthy individuals and patients with T2DM demonstrated that drug exposure increased in a dose-dependent manner. Results from phase II clinical trials indicated that once-daily dutogliptin, in combination with other oral diabetes therapies, reduces postprandial blood glucose and HbA1c levels, both indicators of successful diabetes management. The incidence of adverse events was similar in treatment and placebo groups, with slightly more headache, arthralgia, sinusitis, and dizziness occurring in the 400 mg dutogliptin group compared with placebo. Phase II clinical trial for the myocardial infarction treatment is underway.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98086
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C87493
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY | |||
|
890402-81-0
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY | |||
|
79QH89EV9M
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY | |||
|
SUB32929
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY | |||
|
DTXSID301008624
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY | |||
|
DBSALT002056
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY | |||
|
15949100
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY | |||
|
TT-19
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY | |||
|
100000126386
Created by
admin on Fri Dec 15 17:13:43 GMT 2023 , Edited by admin on Fri Dec 15 17:13:43 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD